Clinical Trial Update: A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating MHB088C injection vs physician's choice in relapsed extensive-stage small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• MHB088C

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Small Cell Lung Cancer Extensive Stage | Phase 3 | Status: RECRUITING